Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Company Overview

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $16.01 to $18.08
• 50-Day Range: $16.34 to $25.19
• 52-Week Range: $16.01 to $28.09
• Volume: 4.29 million shs
• Average Volume: 431,191 shs
• Market Capitalization: $957.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.00
• Consensus Rating: Buy

BCAX Stock Analysis - Frequently Asked Questions

How have BCAX shares performed this year?

Bicara Therapeutics' stock was trading at $25.41 at the beginning of the year. Since then, BCAX shares have decreased by 30.8% and is now trading at $17.59.
View the best growth stocks for 2024 here.

How were Bicara Therapeutics' earnings last quarter?

Bicara Therapeutics Inc. (NASDAQ:BCAX) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by $1.14.

When did Bicara Therapeutics IPO?

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share.

When did Bicara Therapeutics' quiet period expire?

Bicara Therapeutics' quiet period expired on Wednesday, October 23rd. Bicara Therapeutics had issued 17,500,000 shares in its initial public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. During Bicara Therapeutics' quiet period, insiders and underwriters that worked on the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Bicara Therapeutics' major shareholders?

Top institutional investors of Bicara Therapeutics include RA Capital Management L.P. (13.44%), FMR LLC (4.39%), Braidwell LP (3.20%) and Janus Henderson Group PLC (2.30%).
View institutional ownership trends.

How do I buy shares of Bicara Therapeutics?

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCAX
• Previous Symbol: NASDAQ:BCAX
• CUSIP: N/A
• CIK: 2023658
• Web: www.bicara.com
• Phone: (617) 468-4219
• Fax: N/A
• Employees: 32
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $43.00
• High Stock Price Target: $48.00
• Low Stock Price Target: $35.00
• Potential Upside/Downside: +144.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 54,416,000
• Free Float: N/A
• Market Cap: $957.18 million
• Optionable: N/A
• Beta: N/A